The early effects of rapid androgen deprivation on human prostate cancer

The early effects of rapid androgen deprivation on human prostate cancer

The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa).Therefore, understanding how ARs regulate the human transcriptome is of paramountimportance. The early effects of castration on human PCa have not previously beenstudied 27 patients medically castrated with degarelix 7...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Shaw, G, Whitaker, H, Corcoran, M, Dunning, M, Luxton, H, Kay, J, Massie, C, Miller, J, Lamb, A, Ross-Adams, H, Russell, R, Nelson, A, Eldridge, M, Lynch, A, Ramos-Montoya, A, Mills, I, Taylor, A, Arlt, W, Shah, N, Warren, A, Neal, D
Format:	Journal article
Język:	English
Wydane:	Elsevier 2015

Podobne zapisy

The androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in man
od: Sharma, N, i wsp.
Wydane: (2012)

The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.
od: Sharma, N, i wsp.
Wydane: (2013)

Independence of HIF1a and androgen signaling pathways in prostate cancer
od: Tran, MGB, i wsp.
Wydane: (2020)

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
od: Rajan, P, i wsp.
Wydane: (2014)

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy
od: Rajan, P, i wsp.
Wydane: (2014)

CACNA1D overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation
od: McKerr, N, i wsp.
Wydane: (2023)

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
od: Dahlman, A, i wsp.
Wydane: (2010)

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.
od: Asim, M, i wsp.
Wydane: (2017)

Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy
od: Guldvik, IJ, i wsp.
Wydane: (2024)

Clinically relevant fatigue in men with hormonesensitive prostate cancer on long-term androgen deprivation therapy
od: Storey, D, i wsp.
Wydane: (2012)

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer
od: Warren, A, i wsp.
Wydane: (2018)

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells
od: Steiner, I, i wsp.
Wydane: (2023)

Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study
od: Ross-Adams, H, i wsp.
Wydane: (2015)

Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.
od: Storey, D, i wsp.
Wydane: (2012)

Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
od: Higgins, G, i wsp.
Wydane: (2006)

The importance of DNA methylation in prostate cancer development.
od: Massie, C, i wsp.
Wydane: (2016)

Anticancer imidazoacridinone C-1311 is effective in androgen-dependent and androgen-independent prostate cancer cells
od: Niemira, M, i wsp.
Wydane: (2020)

Androgen blockade in prostate cancer - Authors' reply
od: Dalesio, O, i wsp.
Wydane: (2000)

Towards derivation of a distinct signature permitting personalised treatment in prostate cancer
od: Lamb, A, i wsp.
Wydane: (2013)

Towards derivation of a distinct signature permitting personalised treatment in prostate cancer
od: Lamb, A, i wsp.
Wydane: (2012)

Impact of TMPRSS2-ERG fusion gene on prostate cancer cell response to chemotherapy, radiotherapy and androgen deprivation therapy
od: Ovtcharov, S
Wydane: (2015)

Mining human prostate cancer datasets: The "camcAPP" shiny app.
od: Dunning, M, i wsp.
Wydane: (2017)

Role of somatostatin receptor SSRT5-AS1 in predicting biomarkers of primary androgen deprivation therapy on prostate cancer in Indonesian population
od: Soerohardjo, Indrawarman, i wsp.
Wydane: (2022)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
od: Tan, J, i wsp.
Wydane: (2017)

Glycosylation is an androgen-regulated process essential for prostate cancer cell viability.
od: Munkley, J, i wsp.
Wydane: (2016)

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.
od: Handle, F, i wsp.
Wydane: (2019)

Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer.
od: Urbanucci, A, i wsp.
Wydane: (2017)

c-Myc antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks.
od: Barfeld, S, i wsp.
Wydane: (2017)

ANTI-ANDROGENS IN TREATMENT OF PROSTATE-CANCER - REPLY
od: Dalesio, O, i wsp.
Wydane: (1995)

Mechanism of anti-cancer activity of curcumin on androgen-dependent and androgen-independent prostate cancer
od: Abd. Wahab, Nurul Azwa, i wsp.
Wydane: (2020)

Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium
od: Israel, JS, i wsp.
Wydane: (2024)

Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.
od: Reebye, V, i wsp.
Wydane: (2012)

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer
od: Ross-Adams, H, i wsp.
Wydane: (2016)

VPRBP functions downstream of the androgen receptor and OGT to restrict p53 activation in prostate cancer
od: Poulose, N, i wsp.
Wydane: (2022)

HES6 drives a critical AR transcriptional programme to induce castration‐resistant prostate cancer through activation of an E2F1‐mediated cell cycle network
od: Ramos-Montoya, A, i wsp.
Wydane: (2014)

Androgens target prohibitin to regulate proliferation of prostate cancer cells.
od: Gamble, S, i wsp.
Wydane: (2004)

GA-binding protein alpha: an ETS family member with an important role in prostate cancer
od: Sharma, N, i wsp.
Wydane: (2010)

Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo.
od: Pathak, S, i wsp.
Wydane: (2008)

Sequencing the transcriptional network of androgen receptor in prostate cancer
od: Chng, Kern Rei, i wsp.
Wydane: (2013)

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates
od: Buhigas, C, i wsp.
Wydane: (2022)